-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) Shares Acquired by Wolverine Asset Management LLC
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) Shares Acquired by Wolverine Asset Management LLC
Wolverine Asset Management LLC lifted its position in shares of Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU – Get Rating) by 126.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,366 shares of the company's stock after buying an additional 12,495 shares during the quarter. Wolverine Asset Management LLC's holdings in Phoenix Biotech Acquisition were worth $225,000 at the end of the most recent quarter.
Separately, Spartan Fund Management Inc. purchased a new stake in shares of Phoenix Biotech Acquisition during the 1st quarter worth about $629,000.
Get Phoenix Biotech Acquisition alerts:Phoenix Biotech Acquisition Price Performance
Phoenix Biotech Acquisition stock opened at $10.15 on Tuesday. The stock's 50 day moving average price is $10.11 and its 200 day moving average price is $10.09. Phoenix Biotech Acquisition Corp. has a one year low of $9.94 and a one year high of $11.21.
Phoenix Biotech Acquisition Profile
(Get Rating)Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe.
Featured Stories
- Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAXU)
- Here's Why Harley-Davidson is Roaring Higher
- As Mega Caps Get Crushed, This Mid Cap Tech Stock Is Crushing It
- Is The Meta Platforms Stock Meltdown a Rare Buying Opportunity?
- Why Investors Are Suddenly Excited About Vaxcyte
- Saia Stock Is Ready To Switch Gears And Move Higher
Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Wolverine Asset Management LLC lifted its position in shares of Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU – Get Rating) by 126.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,366 shares of the company's stock after buying an additional 12,495 shares during the quarter. Wolverine Asset Management LLC's holdings in Phoenix Biotech Acquisition were worth $225,000 at the end of the most recent quarter.
據最近提交給美國證券交易委員會的文件顯示,金剛狼資產管理公司在第二季度將其在鳳凰生物科技收購公司(納斯達克代碼:PBAXU-GET Rating)的股票持倉量提高了126.6%。該基金在本季度額外購買了12,495股後,持有該公司22,366股股票。金剛狼資產管理公司在最近一個季度末收購的菲尼克斯生物科技公司所持股份價值22.5萬美元。
Separately, Spartan Fund Management Inc. purchased a new stake in shares of Phoenix Biotech Acquisition during the 1st quarter worth about $629,000.
另外,斯巴達基金管理公司(Spartan Fund Management Inc.)在第一季度購買了菲尼克斯生物科技收購的新股份,價值約62.9萬美元。
Phoenix Biotech Acquisition Price Performance
鳳凰生物科技收購價格表現
Phoenix Biotech Acquisition stock opened at $10.15 on Tuesday. The stock's 50 day moving average price is $10.11 and its 200 day moving average price is $10.09. Phoenix Biotech Acquisition Corp. has a one year low of $9.94 and a one year high of $11.21.
鳳凰生物科技收購股票週二開盤報10.15美元。該股的50日移動均線價格為10.11美元,200日移動均線價格為10.09美元。菲尼克斯生物科技收購公司的股價一年來最低為9.94美元,一年最高為11.21美元。
Phoenix Biotech Acquisition Profile
鳳凰生物科技收購簡介
Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe.
菲尼克斯生物科技收購公司沒有重大業務。公司擬與一家或者多家企業實施合併、換股、資產收購、購股、重組或者類似的業務合併。它致力於識別和收購一家專注於美國和歐洲的醫療保健或醫療保健相關行業的企業。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAXU)
- Here's Why Harley-Davidson is Roaring Higher
- As Mega Caps Get Crushed, This Mid Cap Tech Stock Is Crushing It
- Is The Meta Platforms Stock Meltdown a Rare Buying Opportunity?
- Why Investors Are Suddenly Excited About Vaxcyte
- Saia Stock Is Ready To Switch Gears And Move Higher
- 免費獲取StockNews.com關於鳳凰生物科技收購的研究報告(PBAXU)
- 這就是為什麼哈雷-戴維森公司在咆哮
- 隨着Mega Caps被壓垮,這隻中型股科技股正在壓垮它
- Meta平臺股票崩盤是難得的買入機會嗎?
- 為什麼投資者突然對Vaxcell感到興奮
- SAIA股票已做好換擋走高的準備
Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《鳳凰生物科技收購日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對菲尼克斯生物技術收購和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧